BONA LAB MISSION
|
The mission of the Bona Lab is to ensure that every child diagnosed with cancer has an equal chance of survival and optimal quality-of-life during and after treatment.
|
We aim to achieve this by uniting traditional outcomes and health services research with the robust clinical trial model of discovery and care which has steadily improved outcomes for children with cancer over the last half century. Our team is highly collaborative and leverages the expertise of colleagues conducting multicenter clinical trials and basic science translational research to consider risk factors for disease outcome from a novel lens.
|
RESEARCH PROGRAM
Trial-embedded inception cohort studies
These studies embed robust parent-reported sociodeomographic data collection into multi-center clinical trials for children with cancer across the U.S. to identify mechanisms linking social determinants of health and outcomes.
Novel healthcare delivery interventions
We have developed the first poverty-targeted intervention for pediatric cancer and are currently evaluating the feasibility of this direct resource provision intervention in a 2-center randomized study. We have also developed a poverty-targeted intervention of direct, unconditional guaranteed income for low-income families.
Novel Sociodemographic Banking research
We have developed a protocol to systematically collect sociodemographic data in a research databank from families of children with a known or suspected hematologic or oncologic diagnosis and families of children planned to receive cellular therapy for malignant or non-malignant disease.
Collaborative translational research
In collaboration with colleagues across Dana-Farber, we are investigating whether physiologic responses to early childhood adversity (including poverty) may induce treatment resistance.
These studies embed robust parent-reported sociodeomographic data collection into multi-center clinical trials for children with cancer across the U.S. to identify mechanisms linking social determinants of health and outcomes.
- DFCI 16-001 Ancillary Household Material Hardship and Acute Lymphoblastic Leukemia Outcomes
- COG ANBL1531 Ancillary Household Material Hardship and Survival Among Children with High-Risk Neuroblastoma
- COG AALL1731 Ancillary Household Material Hardship and Change in Neurocognitive Function During Acute Lymphoblastic Leukemia Therapy
Novel healthcare delivery interventions
We have developed the first poverty-targeted intervention for pediatric cancer and are currently evaluating the feasibility of this direct resource provision intervention in a 2-center randomized study. We have also developed a poverty-targeted intervention of direct, unconditional guaranteed income for low-income families.
- DFCI 22-635 Pediatric Resource Intervention to Support Equity (PediRISE) Pretest Refinement Study
- DFCI 18-275 Development of the Novel PediCARE Intervention
- DFCI 18-294 Pediatric Cancer Resource Equity Intervention (PediCARE) Pilot Feasibility Study
Novel Sociodemographic Banking research
We have developed a protocol to systematically collect sociodemographic data in a research databank from families of children with a known or suspected hematologic or oncologic diagnosis and families of children planned to receive cellular therapy for malignant or non-malignant disease.
- DFCI 19-796 Environmental Child Health Outcomes (ECHO) Database Protocol
Collaborative translational research
In collaboration with colleagues across Dana-Farber, we are investigating whether physiologic responses to early childhood adversity (including poverty) may induce treatment resistance.
- DFCI 18-152 Effects of Poverty on Enhancer Landscapes in Pediatric B-Cell Acute Lymphoblastic Leukemia (collaboration with the Knoechel Lab)
- DFCI 20-228 Poverty Exposure and GD2 Expression in Neuroblastoma Tumor Samples
HOME | RESEARCH | PEOPLE | PUBLICATIONS | FUNDING/SUPPORT | MEDIA | CONTACT
©2020 Bona Lab at Dana-Farber Cancer Institute
©2020 Bona Lab at Dana-Farber Cancer Institute